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ess: nadams2002@btintSummary Inhaled corticosteroids form the cornerstone of treatment for
most patients with asthma. A range of compounds are available with a wide
range of prescribable doses. In this overview, we summarize the findings
from a number of Cochrane systematic reviews that have examined the relative
benefits of different doses of beclometasone dipropionate, budesonide and
fluticasone propionate when used to treat children and adults. The key findings
are that all inhaled corticosteroids demonstrate a dose–response relationship
for efficacy measures, but most of the benefit in mild-to-moderate severity
disease is gained in the low-to-moderate dose range of each drug. In this
group, high doses of fluticasone lead to small improvements in measures of control
at the expense of a steep increase in the incidence of oral side-effects. In patients
with severe disease who are dependent on oral steroids, there may be appreciable
benefit in reducing oral steroids from very high compared with high doses of
fluticasone.
& 2006 Elsevier Ltd. All rights reserved.Introduction
During the past three decades, a range of potent
synthetic inhaled corticosteroids (ICS) have been
developed for the treatment of asthma, includingElsevier Ltd. All rights reserv
rane reviews cited in this evid
ernet.com (N.P. Adams).beclometasone dipropionate (BDP), budesonide
(BUD) and fluticasone propionate (FP). ICS have
an established position in the management of
asthma in children and adults. They reduce
morbidity and mortality,1 and are recommendeded.
ence-based review.
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management guidelines.2,3 Three systematic re-
views undertaken using the Cochrane methodology
have shown unequivocally that BDP, BUD and FP all
lead to significant improvements in airway func-
tion, as measured by forced expired volume in 1 s
(FEV1) and peak expiratory flow (PEF); a reduced
likelihood of asthma exacerbation; improvement in
symptoms; and a reduced need for rescue beta-2
agonist when any daily dose is compared with
placebo.4–6 Although these reviews have allowed a
quantitative assessment for outcome measures
related to asthma, they cannot provide clear
insights into the relative effects of different doses
because the trials did not randomize participants to
different doses of ICS. Current asthma management
guidelines have been developed on the basis of two
key assumptions. First, that a dose-related differ-
ence in effect may be anticipated (i.e. that a
dose–response phenomenon is shown for ICS).
Therefore, patients with more severe symptoms
or poorer lung function (i.e. poorer control),
may benefit from higher doses. Second, that
patients with more severe underlying disease as
measured by baseline lung function or other
markers of control, such as frequency of symptoms,
may benefit from higher doses compared with
patients with less severe disease. These questions
are best addressed by randomized-controlled trials
(RCTs), in which participants are allocated to
groups in which they receive one of two or more
daily doses of an ICS using the same delivery
system. In this paper, we examine the evidence
presented in a set of Cochrane systematic reviews
of such studies.Cochrane systematic reviews of interest
Four Cochrane systematic reviews addressing
the issue of ICS dose response in asthma have
been published: (1) inhaled beclometasone at
different doses for chronic asthma first published
in 1999;7 (2) inhaled BUD at different doses
for chronic asthma first published in 1999;8 (3)
inhaled fluticasone at different doses for chronic
asthma first published in 2000;9 (4) high dose vs.
low-dose ICS as initial starting dose for asthma in
adults and children first published in 2003.10 In
those trials, the patients with stable asthma were
randomized either to high dose (with subsequent
step down to lower dose) or maintained on low or
medium dose. Henceforth, reviews one to three
will be termed the dose–response reviews, and the
fourth review will be termed the starting-dose
review.Review methodology
Objectives
Each of the dose–response reviews had the primary
objective of assessing whether BDP, BUD and FP had
a dose–response effect for outcomes related to
efficacy and side-effects. The primary objective of
the starting-dose review was to establish whether
patients starting an ICS for asthma control gained
benefits that were dose related (i.e. to establish
the optimal starting dose of ICS in ICS-naı¨ve
participants). Both the dose–response reviews and
the starting-dose review considered all outcome
measures, except those concerned with growth and
bone turnover.
Study inclusion criteria
In the dose–response reviews, the studies had to
have a treatment arm of BDP, BUD or FP compared
with the same ICS at a different dose. The studies
also had to meet the following criteria: (1) have
recruited patients with chronic asthma over the
age of 2 years; (2) be RCTs of parallel group or
crossover design; (3) involve treatment adminis-
tered using a hand-held inhaler device; and (4)
have a treatment period of 1 week or longer. Trials
including patients under the age of 2 years or using
a nebulizer were specifically excluded. The inclu-
sion criteria for the starting-dose review differed
from that of the dose–response reviews in a number
of important respects. Participants were not
permitted to use an ICS for at least 1 month before
randomization, and the duration of treatment was
a minimum of 4 weeks.
Comparisons
In the dose–response reviews, dose comparisons
were not specified a priori. In the BDP and BUD
dose–response reviews, results were reported
according to the fold difference in daily dose of
ICS. In the FP dose–response reviews, dose compar-
isons were made on the basis of the total daily dose
of FP. The authors did, however, arbitrarily define
dose ranges to aid the description of their findings.
These ranges were low-dose range (p200mcg/d),
moderate-dose range (400–500mcg/d), high-dose
range (800–1000mcg/d) and very high-dose range
(41000mcg/d). In the starting-dose review, a
priori-defined dose range comparisons were made.
It is important to appreciate that these dose ranges
differ from those described in the dose–response
reviews. In particular, separate dose ranges were
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Table 1 Dose range comparison groups (mcg/day) for the starting dose review.
BDP/BUD FP
Child Adult Child Adult
Low dose o200 o400 o100 o200
Moderate dose 200 to 400 400 to 800 100 to 200 200 to 400
High dose 4400 4800 4200 4400
BDP, beclometasone dipropionate; BUD, budesonide; FP, fluticasone proprionate.
The dose–response characteristics of inhaled corticosteroids when used to treat asthma 1299defined for adults and children. These are detailed
in Table 1. In the starting-dose review, studies
assessing different ICSs were pooled according to
the pre-defined dose ranges. In the starting-dose
review, studies designed to compare a step
down dose approach to a fixed ICS dose were
analyzed separately. For each of the dose–response
reviews, subgroup analyses based upon asthma
severity were planned. In order to do this,
trials had to be categorized according to severity.
The 1995 consensus guidelines developed by
the global initiative for asthma (GINA) provide
bandings for disease severity. These are based
on degrees of symptom control that apply to
patients before starting treatment or the amount
of treatment required to provide adequate con-
trol.11 An attempt was made in these reviews to
retrospectively categorize the included studies
according to the GINA bandings. In the dose–
response reviews, studies were categorized on the
basis of the presence or absence of regular oral
corticosteroid (OCS) use at enrolment, and were
analyzed separately.Results
Is there evidence for an inhaled
corticosteroid dose response?
In the BDP dose–response reviews, individual trials
evaluated a wide range of comparisons spanning
differences in dose from less than two-fold to five-
fold. Most of these trials were crossover studies
with small patient numbers, and almost all assessed
different daily dose combinations of BDP and could
not be pooled in a meta-analysis. For most out-
comes, no significant differences between doses
were found. Insufficient data were available to
make a reliable assessment of asthma severity. A
meta-analysis including the data from two parallel-
design studies, which compared BDP 800mcg/d
with BDP 400mcg/d, found statistically significantbut small improvements in measures of airway
function favouring the higher dose.12,13 These
included improvements in morning PEF, weighted
mean difference (WMD) 11 L/min 95% confidence
intervals (95% CI) 4–19 L/min and evening PEF, WMD
8 L/min (95% CI 0–16 L/min). No statistical hetero-
geneity was apparent when the results of these
studies were pooled, but it is important to
appreciate that the trials did differ in a number
of important respects. These include the fact that,
in one study, an aerosol metered dose inhaler was
used for the lower dose, whereas a dry powder
inhaler was used for the higher dose.12 The studies
also had widely differing durations: 6 weeks12 to 12
months.13
Mild to moderate asthma in patients not treated
with oral corticosteroids
Most studies in the BUD dose–response reviews that
recruited patients not receiving OCSs at enrolment
were judged to have included patients with mild-
to-moderate asthma. Differences in trial design,
outcomes reported and limited data availability
meant that a meta-analysis was not possible. In the
case of the FP dose–response reviews, most of the
participants included in studies in which OCS use
was an exclusion criterion were judged to have
mild-to-moderate asthma. Four trials included
participants with mild-to-moderate asthma,14–17
11 with moderate asthma,18–28 one with mild,
moderate and severe asthma29 and one with
moderate to severe asthma.30 A meta-analysis of
outcomes reported in the trials comparing FP at
different dose was undertaken. The results are
summarized in Table 2. The data for FEV1 are
presented graphically in Fig. 1. No studies were
included in non-OCS treated patients that included
a very high dose FP (41000mcg/d) treatment
arm. Minimal data were available for comparisons
of moderate dose (400–500mcg/d) compared
with high-dose FP (800–1000mcg/d). For compar-
isons over the low and moderate dose range
(100 vs. 200mcg/d, 100 vs. 400–500mcg/d and
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Figure 1 The effects of fluticasone propionate compared at different dose on FEV1 in mild to moderate asthma.
9 The
data are individual meta-analyses undertaken for studies that compared fluticasone propionate at each dose
comparison. FP, fluticasone propionate; n, number of studies contributing to meta-analysis, N, total number of
participants included in the meta-analysis. The error bars are 95% confidence intervals.
The dose–response characteristics of inhaled corticosteroids when used to treat asthma 1301200 vs. 400–500mcg/d), no dose–response effect
was apparent for FEV1. However, a statistically
significant effect was seen when high-dose FP
(800–1000mcg/d) was compared with low-dose
range FP (200mcg/d), although the additional
benefit was relatively small. For diary card PEF, a
statistically significant dose–response effect was
apparent over most parts of the dose range.
Comparisons of FP in the low-dose range (100 vs.
200mcg/d) showed slightly greater improvements
in morning and evening PEF with the higher
dose. Comparisons between low and moderate
dose (100 or 200mcg/d vs. 400–500mcg/d),
and low (200mcg/d) compared with high dose
(800–1000mcg/d), showed similar magnitude
effects that were greater with the higher dose. By
contrast, for symptom scores, significant differ-
ences between doses favouring the higher dose
were seen in comparisons between low and
moderate dose but not for comparisons between
the high dose and low-dose ranges. No difference
between any dose comparison was seen for rescue
beta-2 agonist use.
Moderate-to-severe asthma
Two studies that assessed BUD at different doses
reported the number of patients who withdrew
because of asthma exacerbation.31,32 Both wereconducted in patients judged to have moderate-to-
severe asthma using GINA criteria. No significant
difference between treatment groups was apparent
for FEV1 (% predicted), WMD 1.4% (95% CI 0.8 to
3.6%) or morning PEF, WMD 2 L/min (95% CI 13 to
16 L/min). However, a significant reduction in
the likelihood of withdrawal due to exacerbation
was apparent for BUD 800mcg/d compared
with 200mcg/d, RR 3.93 (95% CI 1.4–10.9),
corresponding to a number needed to treat (NNT)
of 33 (95% CI 20–100). This result was influenced
strongly by one large high-quality RCT.32 Another
large multicentre study randomized 671 adults
with moderate-to-severe asthma to treatment
for 6 weeks with either FP 1000 or 2000mcg/d.33
A proportion of patients in this trial were receiving
OCSs at enrolment. Only evening PEF showed a
significantly greater improvement favouring
the higher dose of FP: mean difference 7 L/min
(95% CI 0–15 L/min). No difference between the
two doses was apparent for FEV1, morning PEF,
symptom-free days, or daytime/night-time rescue
beta-2 agonist use.
Severe asthma treated by oral corticosteroids
Budesonide. Two studies comparing BUD at differ-
ent doses were undertaken in patients judged to
have suboptimally controlled, severe asthma. In
ARTICLE IN PRESS
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receiving OCS at the time of enrolment. One was
conducted in adults,34 the second in children.35 In
neither were data presented in a form that allowed
inclusion in a meta-analysis. Significant improve-
ments, favouring high-dose BUD over low-dose BUD,
were apparent for a number of outcomes in each
study. In the adult study, FEV1 and morning PEF
both improved on 1600mcg/d compared with
200mcg/d, by 0.13 L (Po0:05) and 18 L/min
(Po0:01), respectively. In the study in children,
BUD 800mcg/d compared with 200mcg/d produced
significantly greater improvements in FEV1 com-
pared with baseline (4% predicted, P ¼ 0:015),
morning PEF (2.3% predicted, Po0:001), and
reduction in daily beta agonist use (16%,
P ¼ 0:036). Only one study evaluated the relative
oral steroid-sparing efficacy of different doses of
BUD.36 This parallel group study in 159 partic-
pants assessed the relative oral prednisolone-
sparing efficacy of BUD 1600 vs. 800mcg/d in
adults. Prednisolone dose tapering was undertaken
using a forced-down titration approach. No sig-
nificant differences were apparent between doses
for either the percentage reduction in daily
prednisolone dose compared with baseline or the
number of patients who were able to discontinue
prednisolone.
Fluticasone. Two parallel group studies were
conducted in patients treated with OCS to test
the effect of FP as an OCS-sparing agent.37,38 Both
were large, multicentre trials of good methodolo-
gical quality conducted in adults with severe
asthma. Dependence upon oral prednisolone for
asthma control at the time of enrolment was an
inclusion criterion for both studies. Two nominal
daily doses of FP were compared in each trial: FP
1000 or 2000mcg/d delivered via the Accuhaler dry
powder inhaler in patients receiving prednisolone
13.0–13.6mg/d, and FP 1500 or 2000mcg/d deliv-
ered via a metered dose inhaler in patients
receiving prednisolone 9.5–10.2mg/d. A high pro-
portion of patients (480%) in both studies were
also receiving treatment with a regular ICS at
enrolment. Reduction in daily dose of oral pre-
dnisolone was the primary outcome measure in
both studies. Both trials were of 16 weeks duration.
Criteria for prednisolone dose reduction were
established a priori in both trials, and were based
around maintenance of stable asthma control in
relation to baseline. The results from these studies
could be pooled. Significantly more patients were
able to discontinue oral steroid therapy with FP
2000mcg/d compared with FP 1000–1500mcg/d,
NNT 6 (95% CI 3–25). Highest dose FP also resulted
in significantly greater reductions in daily oralprednisolone requirement, WMD 2.0mg/d (95% CI
0.1–4.0mg/d).
Is there evidence that starting dose is
important?
Fixed dose comparison
Symptomatic asthma and suboptimal asthma con-
trol were inclusion criteria for many of the studies.
Statistically significant but small improvements
in FEV1 were found for high-dose ICS compared
with moderate dose ICS, WMD 5.3 (% predicted)
(95% CI 0.7–10.0 [% predicted]). No difference
in PEF was seen. When moderate and low-dose
ICS were compared, significant improvements
were observed in morning PEF, WMD 11.1 L/min
(95% CI 1.3–20.9 L/min) and nocturnal symptoms,
standardized mean difference (SMD) 0.3 (95% CI
0.1–0.5).
Step down approach
Studies in adults incorporating a step down versus
constant ICS dose used BUD 800–1600mcg/d redu-
cing to 200mcg/d compared with a constant dose
of 200–400mcg/d; studies in infants compared
nebulized BUD 2mg/d reducing to 0.5mg/d versus
0.5mg/d. A single study in children used FP
1000mcg/d reducing to 100mcg/d versus
200mcg/d. Pooled analyses, including studies that
compared an initial high dose with subsequent step
down to a constant moderate/low ICS dose, showed
no significant differences in lung function, symp-
toms, rescue medications or asthma control be-
tween the two treatment approaches.
Are side-effects dose-dependent?
Oropharyngeal side-effects
Few of the studies that compared different daily
doses of either BDP or BUD in the dose–response
reviews reported the incidence of oropharyngeal
side-effects. A pooled estimate of relative risk (RR)
according to dose could not be calculated. By
comparison, side-effects of FP were reported for a
wide range of doses. A significantly greater risk of
hoarseness/dysphonia was apparent for high-dose FP
(800–1000mcg/d) compared with low-dose FP
(50–100mcg/d) RR 0.14 (95% CI 0.03–0.77). The
corresponding number needed to harm for FP at
high- compared with low-dose was 25 (95% CI
14–100) for a 4–8 week treatment period. No
difference in the likelihood of hoarseness was
apparent for dose comparisons over other parts of
the dose range. No difference in the incidence of
sore throat/pharyngitis or oral candidiasis was
apparent for any FP dose comparison.
ARTICLE IN PRESS
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Effects of treatment on hypothalamo-pituitary axis
(HPA) function were assessed using a number of
measures in the dose–response reviews. These
included basal measurements of HPA activity
(morning plasma cortisol levels, overnight and
24-h urinary cortisol levels), and dynamic tests
of adrenocortical reserve (plasma cortisol levels
after corticotrophin injection or infusion). Few
studies reported these outcomes, and it was not
possible to derive a pooled treatment effect across
studies.Discussion
In this overview, we have summarized four sys-
tematic reviews that examined the evidence for
dose–response effects with BDP, BUD and FP. A
proof-of-principle has been shown, in that all three
ICS reviewed here have evidence of dose-asso-
ciated improvements in one or more outcome
measures. However, it is important to appreciate
that aspects of trial design will influence the
likelihood of detecting such effects. For example,
small and underpowered individual trials cannot
reliably reject the null hypothesis of ‘no differ-
ence’ between treatment arms. Most of the studies
assessing BDP and BUD in mild-to-moderate severity
asthma were of this type. Furthermore, these
studies could not be pooled in a meta-analysis
because of a lack of commonality in outcome
measurements across trials and inadequate
data reporting. The apparent lack of a dose–
response in some outcomes may have been
the consequence of trial size, consistency of
data collection and adequacy of result reporting
rather than any intrinsic properties of BDP or
BUD. By contrast, studies of higher and low-dose
FP often reported the same outcomes, so permit-
ting a more powerful pooled analysis. This revealed
a statistically significant dose–response effect
for a number of outcomes in patients judged to
have asthma of mild-to-moderate severity. How-
ever, the dose–response curve seems to be shallow.
Statistically significant greater improvements in
airway function and symptoms were found when
high-dose FP (800–1000mcg/d) was compared with
lower doses (200mcg/d), but the incremental
advantage was small, as shown for the effect on
FEV1 in Fig. 1.
To set these observations into perspective, it is
worth considering systematic reviews that com-
pared ICSs at different doses to placebo.4–6
Significant gains in asthma control were reported
with nominal daily doses as low as 200mcg (BDP orBUD)4,5 or 100mcg (FP).6 With higher doses (seen
most clearly in the review of FP vs. placebo),6 the
benefit over placebo seems to be greater with
higher doses (Fig. 2). Those trials tested different
doses in different study populations, so the analysis
in Fig. 2 cannot be used as proof of a dose–response
effect—unlike the trials summarized in Fig. 1, in
which patients in the same study populations were
randomized to receive one or other dose. Taken
together, Figs. 1 and 2 suggest very strongly that
the greatest proportional gains in control compared
with no ICS, occur at the lowest dose, with only
modest additional benefits from higher doses.
Although the incremental gain in efficacy with
higher doses seems to be small, in the case of FP
(for which there are adequate data, unlike BDP or
BUD), higher doses may be accompanied by
increased risk of oropharyngeal side-effects. Pau-
city of data and data reporting did not allow an
overall assessment of the effects of dose on HPA
function.
Overall, the systematic reviews reported in this
overview support an approach to asthma manage-
ment that recognizes some variability in control
that is dose dependent and recommends dose
titration according to measures of control. The
British Thoracic Society (BTS/SIGN 2003) guidelines
suggest starting with an ICS dose of 400mcg BDP
equivalent per day, and then titrating down to the
lowest dose needed to maintain control.2 Evidence
from these reviews support these recommenda-
tions. However, the core of patients seem to
require higher doses to achieve control. In
patients with moderately severe and severe asth-
ma, modest additional reductions in asthma ex-
acerbations and improvement in airway function
may be gained from the use of higher rather than
lower dose BUD. Data from studies that specifically
assessed the OCS sparing properties of FP also
suggest that adults can derive clinically worthwhile
reductions in the amount of prednisolone required
to maintain control if very high doses (2000mcg/d)
are used.
There is now a substantial body of evidence to
guide the use of ICSs in asthma. In clinical practice,
regular reassessment of ICS dose requirement by
the clinician and patient in the context of an
asthma management plan should take place. This
will allow tailoring of ICS dose to the individual’s
needs. Trial data will never predict the outcome for
an individual patient in clinical practice, but
doctors and patients can gain reassurance from
the knowledge that most asthmatics will achieve
good control in the lower part of the available ICS
dose range. Future studies of ICS dose–response
should concern long term (412 months) effects on
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Figure 2 The effect of fluticasone propionate on FEV1 compared with placebo in mild-to-moderate asthma.
6 The data
are pooled meta-analyses undertaken for studies that compared each dose of FP with placebo. n, number of studies
contributing to meta-analysis; N, total number of subjects included in meta-analysis. The error bars are 95% confidence
intervals.
N.P. Adams, P.W. Jones1304health status, exacerbations and mortality in
patients with severe asthma. These should be
coupled with assessment of adverse outcomes,
including suppression of adrenal function, bone
turnover and growth in children. These types of
prospective studies will need large patient numbers
if they are to have sufficient power to detect
clinically meaningful differences for such out-
comes.
Practice points
 In mild-to-moderate asthma dose-depen-
dent improvements in markers of control
occur, but the dose–response profile is
shallow and most benefit is gained at low
moderate doses.
 In mild-to-moderate asthma, high doses
of FP are accompanied by a relatively
steep increase in oral side-effects
with little improvement in markers of
control.
 For patients who require ICS, starting with a
moderate dose is as effective as starting
with a high dose and stepping down. A core of patients with severe asthma,
particularily those receiving OCS, will gain
benefit from very high dose ICS.Research directions
 Long-term assessment of the safety char-
acteristics of ICSs, especially in those
groups who will accrue the greatest expo-
sure: children and high-dose users.
 Definition of the effects of moderate, high
and very high dose ICS in severe asthma on
mortality, hospital admissions and health-
related quality of life.References
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